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period: In the period of four as well as eigth – weeks course of treatment with imiqui-
mod 5% cream, therapy resulted in signiﬁcantly higher chance of achieving complete 
clearance. Patients treated with imiquimod more frequently achieved clearance level 
higher than 75% of baseline actinic keratoses compared with the subject in vehicle 
group. Adverse events were more frequently recorded within the group of subjects 
who received imiquimod in comparison with vehicle group. The chance of experienc-
ing local skin reaction such as erythema, ﬂaking/scaling/dryness, scabbing/crusting, 
oedema, vesicles, erosin/ulceration was signiﬁcantly higher in experimental group. 
Imiquimod ﬁve percent cream versus vehicle in long time period: Imiquimod 5% cream 
used 3 times a week for 24 weeks was an effective treatment for actinic keratosis 
measured by the probability of achieving complete clearance and partial clearance rate 
(more than 75% reduction in baseline lesions). Frequency of adverse events and local 
skin reactions was higher during the imiquimod treatment in comparison with 
placebo. Imiquimod ﬁve percent cream versus vehicle in patient with solid organ 
transplants: Treatment with imiquimod 5% cream for 24 weeks in kidney, heart and 
liver transplant patients resulted in signiﬁcantly higher probability of achieving com-
plete and partial clearance rates of actinic keratoses. There were no signiﬁcant differ-
ences in incidence of adverse events between groups. CONCLUSIONS: Imiquimod 
ﬁve percent cream appears to be effective and safe alternative therapy for the treatment 
of actinic keratoses.
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OBJECTIVES: The aim of this study was to compare the 18 months Nd : Yag laser 
incidence rate of two multifocal intra-ocular lenses, ReSTOR® and Acrilisa®, implanted 
by a single surgeon following his usual practice. METHODS: This retrospective study 
was based on all patients implanted with a ReSTOR® or Acrilisa® multi-focal lens 
since Q3–2004 at one site. All patients with either cataract or clear lens were operated 
by the same surgeon. Medical data were obtained from patient charts. 18-months post 
surgical data were obtained from the surgeon’s medical ﬁles and from other ophthal-
mologists, if involved in post-surgical care. Time to Nd : Yag laser analysis was carried 
out using Kaplan-Meier survival curves. Imbalance on confounding variables was 
adjusted with a Cox model. RESULTS: Eighty patients (160 eyes) were bilaterally 
implanted with ReSTOR® and 76 (152 eyes) with Acrilisa®. Patients with ReSTOR® 
were more often male (52.5% versus 30.7%; P  0.01) and younger (63.1 versus 65.8; 
P  0.01). After one year of follow-up, 3.6% of the ReSTOR® eyes had Nd : Yag laser 
versus 6.8% of the Acrilisa® eyes. After 18 months, the incidence rates were 4.6% 
and 26.0%, respectively (P  0.0001). Age was weakly associated with Nd : Yag laser 
(p  0.09). Eyes with Acrilisa® had 5.62 [2.64–14.02; P  0.0002] more chances to 
have Nd : Yag laser than ReSTOR®. This persisted after adjusting on age [Hazard 
Ratio: 6.61; 2.61–16.76; P  0.0001]. CONCLUSIONS: This analysis conducted at 
18 months suggested that following usual surgical practice, ReSTOR® eyes had sig-
niﬁcantly less capsulotomy than those implanted with Acrilisa®. Young population 
were slightly more exposed at Nd : Yag laser. Analyses at two and three years will be 
required to conﬁrm these ﬁndings.
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OBJECTIVES: To assess the association of conjunctival hyperaemia with the ﬁxed 
combinations of latanoprost/timolol (LT/TM) and bimatoprost/timolol (BM/TM) in 
the treatment of ocular hypertension or glaucoma using a systematic review and meta-
analyisis of randomized clinical trials (RCTs). METHODS: A systematic search for 
RCTs published between 2000 and 2009 was conducted in Medline, Embase and 
Controlled Trials Register databases. The outcome measured was the appearance of 
conjunctival hyperaemia in studies comparing the use of either LT/TM or BM/TM 
versus different therapeutic options. Statistical analysis was performed including the 
calculation of odds ratio (OR) and its respective conﬁdence interval, along with the 
inter-trial statistical heterogeneity. A sensitivity analysis was also carried out. 
RESULTS: A total of 16 RCTs comparing LT/TM versus distinct therapeutic alterna-
tives and 5 CT comparing BM/TM versus different therapeutic options fulﬁlled criteria 
to be included in the meta-analysis. Although heterogeneity of both comparisons was 
not very high in both the LT/TM group (Q  24.47; p  0.057; I2  38.7 %) and 
the BM/TM group (Q  5.19; p  0.268; I2  22.94 %), the estimation of the OR by 
the random effects model was considered the most appropriate. According to this 
model the ﬁnal OR for the LT/TM group was 0.56 (IC95%: 0.37–0.83), p  0.05 and 
for the BT/TM group the OR was 0.94 (IC95%: 0.66–1.34), p  0.05. In the sensitivity 
analysis performed, none of the RCTs included in this meta-analysis had an important 
effect in the global estimation of OR. CONCLUSIONS: According to available data, 
the use of LT/TM is associated with a signiﬁcant reduction in the development of 
conjunctival hyperaemia versus the comparators used in the RCTs, whereas the use 
of BM/TM produces a conjunctival hyperaemia rate similar to its comparators.
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OBJECTIVES: To date, quantitative risk beneﬁt has mainly involved the translation 
of Cost-Effectiveness techniques or utility adjusted epidemiological statistics. We aim 
to describe how Discrete Event Simulation “DES” offers the possibility of modelling 
the occurrence of several adverse events and beneﬁcial events simultaneously whilst 
accounting for competing events. METHODS: Firstly, a longitudinal patient database 
is used to identify the target patient population. Secondly, incidence rates for the out-
comes are calculated from the entire database, thereby providing the necessary granu-
larity in terms of the predictive factors for the outcomes. The annual probability for 
each outcome is then assigned to each patient in the cohort and DES generates time 
to each event. Thereby the expected events for an unexposed patient cohort is created 
to which relative risks are applied to model drug exposure. An example using glau-
coma patients is presented using data from The Health Improvement Network. 
RESULTS: We obtained data on 17,652 glaucoma patients who were known to be 
receiving glaucoma therapy at January 1, 2007. Patients were characterised according 
to the principal determinants of the outcomes (heart failure, asthma/COPD exacerba-
tion). The same database provided general population incidence rates for the outcomes 
which were assigned to each patient according to their characteristics. National sta-
tistics provided death rates. The expected events over one year for a cohort of 10,000 
glaucoma patients were: HF  95; asthma/COPD  143; deaths  605. CONCLU-
SIONS: These expected numbers represent the occurrence of events in the natural 
history cohort. They were obtained by summing the outcome probabilities across the 
patient group. They do, however, represent the ﬁrst step in creating a comprehensive 
method for risk-beneﬁt quantiﬁcation via DES and large patient databases; beneﬁt can 
be modelled if expressed as the occurrence of an event. The method will need to 
incorporate uncertainty in all the input parameters and to update the probabilities 
after an event has occurred.
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OBJECTIVES: Estimation of cost-of-illness (COI) of leg ulcers in two German cross-
sectional studies using different methodical approaches. METHODS: A direct and an 
indirect method for cost estimation were utilized. In a nationwide cross-sectional study 
in 33 specialized dermatological, surgical and general-medical wound centres, resource 
consumption and associated costs of venous leg ulcer(s) were collected directly from 
physicians and patients. In a second cross-sectional regional study, involving 147 
institutions (hospitals, residencies, nursing services, dermatological ofﬁces, services for 
homeless and addictives) treating patients with ulcus cruris, resource consumption and 
associated costs were inferred from history, wound condition and actual/previous 
treatments based on standardized cost categories. Main economic parameters in both 
studies were direct, indirect and intangible costs (health related quality of life, HRQoL) 
from the societal perspective. RESULTS: The national study enrolled n  218 patients 
with a mean age of 69.8 years (regional study: n  502, 71 years). Wounds existed 
for 7 (regional 9) years on average. The mean total COI per year and patient was 
a9,569 (a10,624). While direct costs summed up to a8658 (a9851), indirect costs were 
much lower a911 (a772). Of direct costs, a7631 (a9122) were covered by the Statutory 
Health Insurances (SHI) and a1027 (a730) by the patients. For SHI, major cost factors 
were inpatient costs, non-drug treatments and physicians/nurses fees. Moreover, clini-
cal predictors such as wound size, number and duration as well as wound etiology 
and characteristics of care (quality, support) were identiﬁed. All patients were severely 
impaired in their HRQoL, implying a high burden of disease and relevant intangible 
costs. CONCLUSIONS: Chronic leg ulcers generate highly relevant COI. Despite dif-
ferent recruitment and cost estimation methods, both studies resulted in comparable 
direct, indirect and intangible costs; observed differences can be attributed to sample 
characteristics. The results point to early and qualiﬁed disease management in all 
related health services areas.
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OBJECTIVES: To estimate the direct and indirect costs of occupational severe chronic 
hand eczema (OSCHE) in patients refractory to topical corticosteroids from the per-
spective of employer’s mutual insurance companies (EMIC) in Spain. METHODS: An 
employer’s mutual insurance company in Spain usually covers 75% of salaries and 
100% of medical treatments of patients on occupational sick leave. A decision analytic 
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model was developed to perform a cost analysis of OSCHE in patients refractory to 
topical corticosteroids from an employer’s mutual insurance company perspective over 
a one year time horizon. A structured questionnaire was elaborated and answered by 
a Spanish panel of four dermatologists and two occupational physicians, to identify 
therapeutic management and estimate the use of resources associated to OSCHE. The 
clinical information was obtained from published literature and was complemented 
by physicians. The information regarding costs associated to the different types of 
disability was obtained from data of 156 patients from one of the main EMIC in 
Spain. Disabilities are classiﬁed by EMIC in three groups according to the time spent 
on sick leave: Partial disability (3 months), partial permanent disability (24 months) 
and total permanent disability (limited to current profession). RESULTS: Annual total 
costs of OSCHE for a Spanish EMIC were on average over a60,000 per patient. Direct 
costs represented 1.4% and indirect costs 98.6% of total costs. Total permanent dis-
ability was the most important cost driver, representing 69.3% of total costs, although 
only 18% of patients were estimated to reach this type of disability. CONCLUSIONS: 
Disability is the most important predictor of total costs in patients with OSCHE for 
the EMIC in Spain. Indirect costs are by far the most important cost driver (98.6%) 
for this disease. An effective therapy for OSCHE may signiﬁcantly reduce the number 
of disabilities and therefore indirect costs.
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OBJECTIVES: To estimate the total costs of moderate to severe psoriasis patients in 
Spain. METHODS: An observational study was conducted at 123 centers in Spain 
recruiting 1217 patients (60.8% males, mean age 45.1 o 13.9 years, 95.6% with active 
treatment) with moderate (60.8%) to severe (39.2%) psoriasis (VACAP study). Direct 
and indirect resource consumption during the study was collected for every patient 
using patient notebooks. Direct resource use consisted in inpatient hospitalization, 
surgeries, emergency room visits, consultations (primary and secondary care, nursery, 
other health care professionals and alternative medicine visits), laboratory and diag-
nostic tests, medication (prescription and non-prescription drugs paid by patients), 
and phototherapy sessions. Indirect costs included productivity losses (full or part-
time), social assistance and out-of-pocket expenses paid directly by patients (travel 
costs, formal caregivers). Resource use unitary costs were obtained from e-Salud 
database. Four-month costs were extrapolated to annual costs (a, year 2009 values). 
RESULTS: Mean annual total cost per patient was a6881 (95% conﬁdence interval 
[CI], a5365–a8370). Direct and indirect costs accounted for a6420 (95%CI, a5067–
a7745) and a461 (95%CI, a299–a625) representing 93.3% and 6.7% of total esti-
mated costs respectively. The most important categories of direct costs were 
prescription medication (a3667, 95%CI, a2954–a4381, 53.3% of direct costs), pho-
totherapy sessions (a1405, 95%CI, a1144–a1666, 20.4%), consultations (a517, 
95%CI, a434–a567, 7.5%) and hospital day visits (a436, 95%CI, a294–a578, 6.3%) 
The most signiﬁcant indirect costs were loss of productivity (a357, 95%CI, a216–
a500, 77.5% of indirect costs) and travel costs (a85, 95%CI, a76–a95, 18.5%). 
CONCLUSIONS: In Spain, mean annual cost per patient with moderate to severe 
psoriasis represents a6881, of which 93% were direct costs and 7% indirect costs.
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OBJECTIVES: This study estimated the economic consequences of topical moxiﬂoxa-
cin compared with topical oﬂoxacin in the treatment of acute infectious conjunctivitis 
in Scotland (SC), Spain (ES) and The Netherlands(NL). METHODS: The rates of 
treatment failure, deﬁned as no improvement or worsening symptoms, were estimated 
by a meta-analysis of randomized controlled trials (RCT) of moxiﬂoxacin. The 
resources consumed and costs of treatment failure were assessed by a survey of 39 
General Practitioners (GP) and 14 Ophthalmologists (OPH). National databases were 
used to estimate resource costs. The potential economic beneﬁt was estimated, and 
sensitivity analyses were performed using moxiﬂoxacin’s failure rate advantage from 
trials directly comparing the drugs and meta-analysis of patients with conﬁrmed bacte-
rial infection (from 3.3% to 6.5% lower). RESULTS: Treatment failure costs are 
driven by extra physician consultations,and bacterial cultures. The average cost of a 
treatment failure in ES, SC and NL respectively is a38, a72, a53 when managed by a 
GP compared to OPH estimates of a108, a133, and a215. OPH extremes were a93 
to a279a. Assuming 1.5% of the population experiences acute infectious conjunctivitis 
and a 10% failure rate in symptomatic improvement in control group patients, the 
estimated annual cost of failure ranges from a57,000a to a322,500 per million inhabit-
ants. Primarily OPH use the studied drugs. With 4.7% less treatment failure when 
moxiﬂoxacin instead of oﬂoxacin is used by OPH, the economic beneﬁt was estimated 
at a5.1, a6.3, a10.13 per patient in ES, SC and NL respectively. This is a cost saving 
of approximately 11% on specialist treatment independent of the country. Sensitivity 
analysis resulted in an economic beneﬁt from a3.58 to a14.01 as extremes of all 
countries. CONCLUSIONS: The decrease of treatment failure rate using moxiﬂoxacin 
instead of oﬂoxacin in acute infectious conjunctivitis provides an economic beneﬁt in 
three countries of interest.
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OBJECTIVES: Acute otitis media (AOM) is the most common childhood infection 
next to common cold. The impacts of AOM deserve attentions from both public health 
and economic perspectives. Taiwan’s National Healthcare Insurance (NHI) provides 
comprehensive coverage and to date, over 97% of the populations are insured. In this 
study we use the NHI claim database to evaluate the economic impacts of AOM. 
METHODS: We reviewed the claims of pediatric patients with AOM who had 
received treatment during January 1–December 31, 2006. Numbers of visits and 
expenses (in $New Taiwan Dollars, exchange rate with $USD 32^33.5 during year 
2006) were calculated. The data size is around 400 gigabytes. RESULTS: The mean 
age of disease was 5.4 years-old. With 29.6 % under 3 years-old, 48.1% under 7 
years, and 22.3 % under 12 years-old. The male: female ratio was: 1.2:1. There were 
733,546 visits related to the occurrence of AOM, 717,263 (visits) occurred in outpa-
tient settings; 16,283 admissions were related to AOM care. A total of 45.8% 
(328,517 out of 717,263 visits) were treated by pediatricians, 35.2% (252,347 visits) 
were treated by otolaryngologists, and 4.6% (34,840 visits) were treated by family 
practitioners. Around 97.0% (15,799 out of 16,283 admissions) were under pediatric 
and 1.7% (281) were under otolaryngology services. The total annual expenses related 
to AOM care was 554,507,868 $NTD, comprising of 315,671,421 $NTD in outpa-
tient (56.9%), and 238,836,447 $NTD in inpatient cares (43.1%). In average, AOM 
took 3.6 antibiotics-days, and 4.5 admission-days to treat. CONCLUSIONS: Over 
half of the AOM care expenses were spent in ambulatory services. Pediatricians took 
46% outpatient and 97% inpatient AOM care resources. The nation-wide economic 
impact of AOM was around 0.55 billion $NTD annually. The NHI claim database 
provides possibility for further economic analysis.
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OBJECTIVES: To compare the cost of cataract surgery in patients with and without 
astigmatism, as reported in the French national Diagnosis Related Group (DRG) 
database (PMSI: Programme de Médicalisation des Systèmes d’Information). 
METHODS: The 2007 DRG database was used. Patients with cataract surgery were 
identiﬁed by the surgery procedure codes (BFGA001-BFGA010; BFLA001-BFLA004). 
Patients with declared astigmatism had a H522 ICD10 code. DRG standard cost was 
adjusted according to the number of procedures. Surgery and anaesthesia costs esti-
mated from the Echelle National des Coûts were adjusted with the same method. 
Average costs were calculated in both groups. Student t-test and chi-square were used 
to compare the two groups. RESULTS: A total of 475 declared astigmatic and 579,778 
without declared astigmatism patients were extracted (age: 73.6 years, 2 males: 3 
females). Astigmatic patients were more often operated on in a private hospital. 
Astigmatic patients showed a trend towards a longer length of stay (2.41 versus 2.17 
days; p  0.12, ambulatory patients excluded), more co-morbidity (2.38 versus 1.03; 
P  0.001) and more procedures (3.03 versus 2.43; P  0.001). The cost of procedures 
was higher for astigmatic patient (a580 versus a464) leading to a higher total hospital 
cost (a1488 versus a1372). CONCLUSIONS: Astigmatism is dramatically under-
reported in the PMSI database in comparison to nationwide prevalence rate estimates. 
Astigmatic patients required more procedures, partially due to increased co-morbidity. 
An astigmatic patient costs more and this is not taken into account by today’s V11 
clustering cost algorithm. Time and motion analysis should be conducted to better 
understand astigmatism management during cataract surgery.
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OBJECTIVES: Psoriasis is a chronic disease with signiﬁcant psychosocial morbidity 
and lower health-related quality of life (QoL). In Sweden, an estimated 250,000 
persons or nearly 3% of the population have psoriasis. There are few studies on the 
total cost of psoriasis therapy, especially studies that take both direct and indirect 
costs into account. The aim of the present study was to analyse and estimate health 
related QoL and costs of psoriasis during a year in relation to disease severity among 
psoriasis patients, based on patient populations from two dermatology centres in 
Sweden. METHODS: The study is based on data from three sources; a patient survey, 
a retrospective chart review, and data from a drug registry. Information about Qol 
